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ROactive in Patients
ith Type 2 Diabetes and
revious Myocardial Infarction
winging the Sword of Damocles?*†
ukka Westerbacka, MD, PHD
elsinki, Finland
ype 2 diabetes increases the risk of coronary heart disease
t least by 2- to 3-fold. Patients with type 2 diabetes without
history of myocardial infarction (MI) have the same risk
or fatal MI as nondiabetic subjects with a history of MI
1,2). Moreover, type 2 diabetic patients with previous MI
re even more susceptible to coronary events and need all
vailable evidence-based tools for cardiovascular risk reduc-
ion. Thiazolidinediones or glitazones are selective ligands
f peroxisome-proliferator-activated receptor (PPAR)-
amma addressing insulin resistance, a culprit of the meta-
olic syndrome and type 2 diabetes (3). Currently, 2
idely used compounds of thiazolidinediones, pioglitazone
nd rosiglitazone, have been approved for the treatment of
yperglycemia in type 2 diabetes. Because of their effect on
See page 1772
lleviating insulin resistance, hyperglycemia, and metabolic
bnormalities related to insulin resistance such as dyslipide-
ia and inflammation, there has been great interest in
hether these drugs could decrease the cardiovascular com-
lications in type 2 diabetic patients. In this issue of the
ournal, results of 2,445 patients with type 2 diabetes and
revious MI patients from a substudy of the PROactive
PROspective pioglitaAzone Clinical Trial In macroVascu-
ar Events) study are reported (4).
The primary end point of the PROactive study was the
rst occurrence of any of the events defined in a composite
nd point of both diseases (all-cause mortality, nonfatal MI,
Editorials appearing in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
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elsinki, Finland. Dr. Westerbacka has received honoraria for lecturing for manu-
acturers of pioglitazone (Eli Lilly) and rosiglitazone (GlaxoSmithKline).onfatal stroke, acute coronary syndrome) and procedures
coronary or leg revascularization or leg amputation). Inclu-
ion of both disease and procedure end points has been
riticized (5) and may also have influenced the results in this
ubstudy. As in the main study population (6), the primary
nd point did not differ between the pioglitazone and
lacebo group in the substudy of patients with previous MI
p 0.135). The study group also defined a main secondary
nd point including death, nonfatal MI, and stroke. The
efinition of this end point was released only 12 days before
ocking the database and has led to a lively debate. Although
he effect of pioglitazone on the main secondary end point
as significant in the main PROactive study, this was not
he case in this substudy (p 0.0585), perhaps owing to the
ecreased statistical power when compared with the main
tudy and the fact that the study was closed prematurely.
owever, the study group had another statistical analysis
trategy for the substudy finalized before the unblinding the
tudy, which could be criticized for resembling a fishing
pproach. These 3 prespecified end points in the present
tudy (4) consisted of different combinations of MI, cardio-
ascular death, and stroke. From these end points, only one,
atal or nonfatal MI, was significantly different between the
roups (p  0.0453). The reason may be that there was
ore heart failure (HF) in the pioglitazone group (defined
arlier), contributing to cardiovascular death, which was
ncluded in the other composite end points. In post-hoc
nalysis, the incidence of acute coronary syndrome was
odestly but significantly decreased in the pioglitazone
roup (p  0.0346), whereas there were no differences in
ll-cause mortality, cardiac death, nonfatal MI, coronary
evascularization, or stroke.
In the substudy, the decrease of glycosylated hemoglobin A1c
n the pioglitazone group was 0.8% (0.4% decrease in
lacebo group) and was similar to that observed in the main
ROactive study. It is important to notice that in PROac-
ive the pioglitazone/placebo was added to all other medi-
ations, including other glucose-lowering medications. De-
rease in hyperglycemia can be considered noteworthy and
ould in part explain the beneficial effects on the MI end
oints as shown in the UKPDS (United Kingdom Prospec-
ive Diabetes) Study (7). Also, the other effects of pioglita-
one on cardiovascular risk factors could be involved (3). As
lso shown in this study, pioglitazone increases serum
igh-density lipoprotein cholesterol and decreases serum
riglycerides and, in that sense, is more beneficial than
osiglitazone (3). As there are data that glitazones may also
lleviate inflammation, it is unfortunate that no serum
amples were collected for analyzing these effects. In this
tudy, approximately 33% of the patients were receiving
nsulin therapy at baseline; insulin use increased to 36% in
he pioglitazone group and to 46% in the placebo group,
emonstrating the insulin-sensitizing effect of pioglitazone.
he use of insulin was more common in this subgroup with
revious MI when compared to those without history of MI.
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Editorial Comment May 1, 2007:1781–2n essential observation was that use of insulin was associ-
ted with increase in MI (hazard ratio [HR] 1.59, p 
.0053). This merits a re-evaluation of the use of glitazones
n combination therapy with insulin in all insulin-treated
atients in a routine clinical practice. Indeed, in Europe, use
f insulin has been a contraindication for glitazones, al-
hough the latest American Diabetes Association/European
ssociation for the Study of Diabetes guidelines also rec-
mmend this option (8).
The worrying increase in edema and HF has been
elatively consistently reported in glitazone trials. This
eems to be a class effect of glitazones. In the DREAM
Diabetes Reduction Assessment With Ramipril and Ros-
glitazone Medication) study, including 5,269 subjects, ros-
glitazone was used in subjects with either impaired glucose
olerance or fasting glucose but with no evidence of cardio-
ascular disease. In the DREAM study, the incidence of HF
as 0.5% in the rosiglitazone group and 0.1% in the placebo
roup (HR 7.03 with a confidence interval of 1.60 to 30.9)
9). However, in the ADOPT study, including 4,360
atients with type 2 diabetes and reasonably good metabolic
ontrol, the rosiglitazone group had similar incidence of HF
o the metformin group (1.5% vs. 1.3%, rosiglitazone vs.
etformin) but increased incidence when compared with
he sulphonylurea group (0.6%) (10). Patients with previous
I are at increased risk of HF, and this was also true in this
ROactive substudy. The numbers of any reported HF and
F leading to hospitalization were significantly higher in
he pioglitazone group when compared with the placebo
roup. Emphasizing the poorer prognosis of those with
revious MI, the number of HFs was higher in this
ubstudy when compared with those with no previous MI in
he main PROactive study. For clinicians, the increased risk
f HF with glitazones means more careful decision-making
hen optimizing the treatment of type 2 diabetic patients
ith previous MI. In general, the number-needed-to-treat
hould be accompanied by the number-needed-to-harm to
etter estimate the benefits of the treatments.
To summarize, pioglitazone treatment in patients with
revious MI may provide modest additional benefit, which
ould have been more evident in the PROactive substudy ifhe number of patients were larger and the duration of the
tudy were longer. However, clinicians should weigh the
enefits against the fact that the incidence of HF is
ncreased, which is especially important in patients with a
istory of MI. After all, the risk of HF is present and is
efinitely a cardiac end point not to be neglected.
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